Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 5/20 | 0.35 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.33 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520079 | 0.84 | CISD1 (0.63) | CISD1GLAGAACA2CA9 | |
| SCHEMBL9664445 | 0.84 | CA1 (0.60) | CISD1GLAGAACA2CA9 | |
| SCHEMBL17466326 | 0.83 | CISD1 (0.41) | CISD1GLAGAACA2CA9 | |
| SCHEMBL18176624 | 0.83 | CISD1 (0.53) | CISD1GLAGAATYR | |
| SCHEMBL14015364 | 0.82 | CISD1 (0.43) | CISD1GLAGAACA2CA9 | |
| SCHEMBL1404369 | 0.82 | CISD1 (0.39) | CISD1GLAGAACA2CA9 | |
| SCHEMBL18632018 | 0.82 | CISD1 (0.43) | CISD1GLAGAACA2CA9 | |
| SCHEMBL30526137 | 0.82 | CISD1 (0.56) | CISD1GLAGAACA2CA9 | |
| SCHEMBL7910581 | 0.81 | GLA (0.53) | CISD1GLAGAACA2CA9 | |
| SCHEMBL31578652 | 0.80 | CISD1 (0.54) | CISD1GAACA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996039129-A1 | METHODS OF INCREASING AMYLOID DEPOSITION | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-12-12 | — | — | WO | claimed |
| US-20160027592-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTRICITY STORAGE DEVICE USING SAME | UBE INDUSTRIES, LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| WO-1996039129-A1 | METHODS OF INCREASING AMYLOID DEPOSITION | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CISD1 4229/4885GLA 25/4885GAA 19/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CISD1 4229/4885GLA 25/4885GAA 19/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | CISD1 4229/4885GLA 25/4885GAA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.